|
1
|
Ilieș M, Uifălean A, Pașca S, Dhople VM, Lalk M, Iuga CA, Hammer E. From Proteomics to Personalized Medicine: The Importance of Isoflavone Dose and Estrogen Receptor Status in Breast Cancer Cells. J Pers Med 2020; 10:jpm10040292. [PMID: 33352803 PMCID: PMC7766658 DOI: 10.3390/jpm10040292] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/13/2020] [Accepted: 12/17/2020] [Indexed: 01/06/2023] Open
Abstract
Continuing efforts are directed towards finding alternative breast cancer chemotherapeutics, with improved safety and efficacy profiles. Soy isoflavones represent promising agents but, despite extensive research, limited information exists regarding their impact on the breast cancer cell proteome. The purpose of this study was to compare the proteomic profiles of MCF-7 (estrogen responsive) and MDA-MB-231 (estrogen non-responsive) breast cancer cells exposed to different concentrations of genistein, daidzein, and a soy seed extract, using a high throughput LC–UDMSE protein profiling approach. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay confirmed the dual activity of soy isoflavones on MCF-7 cells and the inhibitory effect on MDA-MB-231 cells. Proteome profiling of paramagnetic beads prepared peptides by nano-LC UDMSE and pathway enrichment analysis revealed that isoflavones affected distinct molecular pathways in MCF-7 and MDA-MB-231 cells, such as tyrosine kinases signaling pathway, cytoskeleton organization, lipid and phospholipid catabolism, extracellular matrix degradation and mRNA splicing. Also, in MCF-7 cells, low and high isoflavone doses induced different changes of the proteome, including cell cycle alterations. Therefore, the expression of estrogen receptors and the isoflavone dose are determinant factors for the molecular impact of isoflavones and must be taken into account when considering adjuvant breast cancer therapy towards personalized medicine.
Collapse
Affiliation(s)
- Maria Ilieș
- MedFuture Research Center for Advanced Medicine, Department of Proteomics and Metabolomics, “Iuliu Hațieganu” University of Medicine and Pharmacy, no. 4–6 Louis Pasteur st., 400349 Cluj-Napoca, Romania; (M.I.); (S.P.); (C.A.I.)
| | - Alina Uifălean
- Department of Pharmaceutical Analysis, Faculty of Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy, Louis Pasteur Street 6, 400349 Cluj-Napoca, Romania
- Correspondence:
| | - Sergiu Pașca
- MedFuture Research Center for Advanced Medicine, Department of Proteomics and Metabolomics, “Iuliu Hațieganu” University of Medicine and Pharmacy, no. 4–6 Louis Pasteur st., 400349 Cluj-Napoca, Romania; (M.I.); (S.P.); (C.A.I.)
- Department of Hematology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Vishnu Mukund Dhople
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Felix-Hausdorff-Straße 8, 17475 Greifswald, Germany; (V.M.D.); (E.H.)
| | - Michael Lalk
- Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17489 Greifswald, Germany;
| | - Cristina Adela Iuga
- MedFuture Research Center for Advanced Medicine, Department of Proteomics and Metabolomics, “Iuliu Hațieganu” University of Medicine and Pharmacy, no. 4–6 Louis Pasteur st., 400349 Cluj-Napoca, Romania; (M.I.); (S.P.); (C.A.I.)
- Department of Pharmaceutical Analysis, Faculty of Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy, Louis Pasteur Street 6, 400349 Cluj-Napoca, Romania
| | - Elke Hammer
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Felix-Hausdorff-Straße 8, 17475 Greifswald, Germany; (V.M.D.); (E.H.)
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, 17475 Greifswald, Germany
| |
Collapse
|